We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Registers a Bigger Fall Than the Market: Important Facts to Note
Read MoreHide Full Article
Pfizer (PFE - Free Report) closed the most recent trading day at $25.57, moving -3.27% from the previous trading session. This change lagged the S&P 500's 0.24% loss on the day. Meanwhile, the Dow lost 0.62%, and the Nasdaq, a tech-heavy index, added 0.23%.
Shares of the drugmaker witnessed a gain of 5.38% over the previous month, beating the performance of the Medical sector with its gain of 2.79%, and the S&P 500's gain of 1.31%.
Market participants will be closely following the financial results of Pfizer in its upcoming release. It is anticipated that the company will report an EPS of $0.61, marking a 3.17% fall compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $18 billion, indicating a 1.33% upward movement from the same quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $3.13 per share and revenue of $62.85 billion. These totals would mark changes of +0.64% and -1.23%, respectively, from last year.
Any recent changes to analyst estimates for Pfizer should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.05% upward. Pfizer currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Pfizer is presently being traded at a Forward P/E ratio of 8.44. This signifies a discount in comparison to the average Forward P/E of 14.11 for its industry.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 198, this industry ranks in the bottom 20% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Registers a Bigger Fall Than the Market: Important Facts to Note
Pfizer (PFE - Free Report) closed the most recent trading day at $25.57, moving -3.27% from the previous trading session. This change lagged the S&P 500's 0.24% loss on the day. Meanwhile, the Dow lost 0.62%, and the Nasdaq, a tech-heavy index, added 0.23%.
Shares of the drugmaker witnessed a gain of 5.38% over the previous month, beating the performance of the Medical sector with its gain of 2.79%, and the S&P 500's gain of 1.31%.
Market participants will be closely following the financial results of Pfizer in its upcoming release. It is anticipated that the company will report an EPS of $0.61, marking a 3.17% fall compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $18 billion, indicating a 1.33% upward movement from the same quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $3.13 per share and revenue of $62.85 billion. These totals would mark changes of +0.64% and -1.23%, respectively, from last year.
Any recent changes to analyst estimates for Pfizer should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.05% upward. Pfizer currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Pfizer is presently being traded at a Forward P/E ratio of 8.44. This signifies a discount in comparison to the average Forward P/E of 14.11 for its industry.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 198, this industry ranks in the bottom 20% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.